Unconventional Immunotherapies in Cancer: Opportunities and Challenges

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Conventional immunotherapies like immune checkpoint blockade and CAR-T cells have advanced cancer treatment but face challenges such as tumor resistance and T-cell exhaustion, especially in solid tumors.
• These limitations hinder the efficacy and persistence of existing treatments, necessitating the exploration of alternative therapeutic strategies.

Purpose of the Study:

• To review emerging unconventional immunotherapies and biologics for cancer treatment.
• To highlight the distinct features and potential of these novel platforms in overcoming current therapeutic barriers.
• To discuss strategies for addressing translational challenges and advancing these therapies toward clinical application.

Main Methods:

• Review of current literature on unconventional immunotherapy platforms and biologics.
• Exploration of diverse immune cell subsets (e.g., gamma delta T cells, invariant natural killer T cells) and synthetic biologics (e.g., bispecific antibodies, cytokine fusions).
• Discussion of engineering approaches, overcoming translational challenges (e.g., AI for patient stratification), and future research directions.

Main Results:

• Unconventional platforms offer unique advantages such as MHC independence, tissue-homing, and bridging innate and adaptive immunity.
• Biologics like bispecific antibodies and oncolytic viruses demonstrate potential for modular engineering and off-the-shelf use.
• Novel strategies including metabolic reprogramming, gene editing, and AI are being developed to enhance efficacy and overcome resistance.

Conclusions:

• Unconventional immunotherapies represent a significant advancement, extending the therapeutic potential of cancer immunotherapy, particularly for solid tumors.
• These platforms offer scalable, efficient, and potentially cost-effective treatment options.
• Continued research into mechanistic insights and manufacturing is crucial for realizing the full clinical potential of these innovative therapies.